Literature DB >> 476642

Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.

D Roberts, C Peck, S Hilliard, W Wingo.   

Abstract

Treatment with methotrexate (MTX) plus 1-beta-D-arabinofuranosylcytosine (ara-C) on Days 1, 4, and 7 after i.p. inoculation of L1210 ascites cells was more effective than treatment with one drug on Days 1, 4, and 7 followed by the second drug on Days 2, 5, and 8. Simultaneous treatment with both drugs was associated with a retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP) but no increase in the activity of deoxycytidine kinase in L1210 cells, whereas pretreatment with MTX 24 hr before the administration of ara-C was associated with approximately 2-fold increases in the level of ara-CTP and of deoxycytidine kinase in L1210 cells. However, from 5 hr after treatment with ara-C, higher levels of ara-CTP were observed in L1210 cells treated simultaneously with both drugs than in cells from animals pretreated with MTX 24 hr before treatment with ara-C. The superiority of simultaneous treatment over sequential treatment and the synergism between MTX and ara-C, previously reported for this schedule of simultaneous treatment, are attributed in part to the MTX-induced retention of ara-CTP and the increased exposure of L1210 cells to ara-CTP that results from the slower clearance of ara-CTP.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 476642

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  Biochemical interactions between methotrexate and 1-beta-D-arabinofuranosylcytosine in hematopoietic cells of children: a Pediatric Oncology Group study.

Authors:  E M Newman; D G Villacorte; A M Testi; R A Krance; M B Harris; Y Ravindranath; D Pinkel
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study.

Authors:  Ronald Dubowy; Michael Graham; Nasrollah Hakami; Morris Kletzel; Donald Mahoney; Edward Newman; Yaddanapudi Ravindranath; Bruce Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2008-05       Impact factor: 1.289

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.